Nektar Therapeutics (NKTR) Misses Q1 EPS by 1c, Miss on Revenues
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $66.84 --0%
Revenue Growth %: -11.4%
Financial Fact:
Research and development: 51.95M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: -11.4%
Financial Fact:
Research and development: 51.95M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.42), $0.01 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $24.7 million versus the consensus estimate of $26.8 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
- AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c
- Exelon (EXC) PT Lowered to $49 at Argus
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
